Clinical Trial

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 8, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD). This study is testing the health of the blood vessels and the activity of the nerves that control the blood vessels in adults with insulin resistance. The extent to which ascorbic acid (Vitamin C) improves the function of the blood vessels will be determined. The primary outcome is blood pressure, which is the result of blood vessel health and activity of the nerves, and the reduction in blood pressure that is observed with ascorbic acid.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-01-14; most recent amendment 2025-06-04.
Status change: Not Yet Recruiting → Recruiting 2021-06-25
Trial Details
NCT Number NCT04715022
Lead Sponsor University of Kansas Medical Center
Conditions Hypertension, Cardiovascular Diseases
Enrollment 23 participants
Start Date 2021-06-17
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-08